The Use of Human Liver Cell Model and Cytochrome P450 Substrate—Inhibitor Panel for Studies of Dasatinib and Warfarin Interactions


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The possibility of interactions between warfarin and dasatinib and their interactions with other drugs metabolized by cytochrome P450 isoform CYP3A4 was demonstrated using a previously created cytochrome P450 substrate—inhibitor panel for preclinical in vitro studies of drug biotransformation on a 3D histotypical microfluidic cell model of human liver (liver-on-a-chip technology). Dasatinib and warfarin are inhibitors of CYP2C19 isoform and hence, can interfere the drugs metabolized by this isoform. Our findings are in line with the data obtained on primary culture of human hepatocytes and suggest that the model can be used in preclinical in vitro studies of drugs.

About the authors

A. A. Zakharyants

BioClinicum Center

Email: o.burmistrova@bioclinicum.com
Russian Federation, Moscow

O. A. Burmistrova

BioClinicum Center

Author for correspondence.
Email: o.burmistrova@bioclinicum.com
Russian Federation, Moscow

A. A. Poloznikov

BioClinicum Center

Email: o.burmistrova@bioclinicum.com
Russian Federation, Moscow


Copyright (c) 2017 Springer Science+Business Media New York

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies